Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MLAB 
Mesa Laboratories Inc (MLAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: MLAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $95
1 Year Target Price $95
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.77% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 434.05M USD | Price to earnings Ratio - | 1Y Target Price 95 |
Price to earnings Ratio - | 1Y Target Price 95 | ||
Volume (30-day avg) 4 | Beta 0.9 | 52 Weeks Range 55.21 - 154.03 | Updated Date 12/12/2025 |
52 Weeks Range 55.21 - 154.03 | Updated Date 12/12/2025 | ||
Dividends yield (FY) 0.81% | Basic EPS (TTM) -0.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.64% | Operating Margin (TTM) 7.78% |
Management Effectiveness
Return on Assets (TTM) 2.13% | Return on Equity (TTM) -0.93% |
Valuation
Trailing PE - | Forward PE 35.21 | Enterprise Value 604060701 | Price to Sales(TTM) 1.77 |
Enterprise Value 604060701 | Price to Sales(TTM) 1.77 | ||
Enterprise Value to Revenue 2.46 | Enterprise Value to EBITDA 14.01 | Shares Outstanding 5522299 | Shares Floating 5349009 |
Shares Outstanding 5522299 | Shares Floating 5349009 | ||
Percent Insiders 5.44 | Percent Institutions 92.56 |
Upturn AI SWOT
Mesa Laboratories Inc
Company Overview
History and Background
Mesa Laboratories, Inc. was founded in 1984 by Dr. Alan V. Schilowitz. Initially focused on the development and manufacture of biological indicators and chemical indicators for sterilization processes, the company has grown through organic expansion and strategic acquisitions. Mesa has evolved into a diversified life sciences company providing critical products and services for healthcare, industrial, and environmental applications.
Core Business Areas
- Sterilization and Validation: This segment focuses on the development, manufacture, and sale of biological and chemical indicators, along with associated validation and calibration services, used to ensure the effectiveness of sterilization processes in healthcare facilities and pharmaceutical manufacturing.
- Process Analytics: This segment offers a range of instruments and services for measuring, monitoring, and controlling critical parameters in industrial and environmental processes, including temperature, humidity, pressure, and gas concentration. Products include data loggers, calibration equipment, and process analyzers.
Leadership and Structure
Mesa Laboratories is led by a Board of Directors and a management team. Key leadership roles typically include a Chief Executive Officer (CEO), Chief Financial Officer (CFO), and heads of various operational and functional departments. The company operates with a matrix structure, aligning functional expertise with business segment responsibilities.
Top Products and Market Share
Key Offerings
- Description: Mesa's biological indicators (e.g., SporeStrips, ProGauze) are used to confirm the effectiveness of steam, ethylene oxide, and other sterilization methods. They are a critical component for regulatory compliance in hospitals and medical device manufacturers. Competitors include 3M, STERIS, and Crosstex.
- Market Share Data: Specific market share data for individual products is not readily disclosed, but the company is a significant player in the sterilization validation market.
- Product Name 1: Biological Indicators for Sterilization
- Revenue Contribution: Part of the Sterilization and Validation segment, which is a substantial revenue driver.
- Description: Mesa provides on-site and off-site calibration and validation services for a wide array of scientific and industrial equipment, ensuring accuracy and compliance. This service is crucial for pharmaceutical, biotechnology, and food & beverage industries. Competitors include numerous regional and national calibration service providers.
- Market Share Data: Not publicly available.
- Product Name 2: Calibration and Validation Services
- Revenue Contribution: Contributes to both the Sterilization and Validation and Process Analytics segments.
- Description: The Process Analytics segment offers various data loggers (e.g., Loggers) used for monitoring environmental conditions in critical applications such as cold chain logistics, pharmaceutical storage, and environmental testing. Competitors include Sensitech, MadgeTech, and Onset.
- Market Share Data: Not publicly available.
- Product Name 3: Temperature and Humidity Data Loggers
- Revenue Contribution: Part of the Process Analytics segment.
Market Dynamics
Industry Overview
Mesa Laboratories operates within the broader life sciences and industrial instrumentation sectors. The sterilization and validation market is driven by stringent regulatory requirements, increasing healthcare awareness, and the growth of the pharmaceutical and medical device industries. The process analytics market is influenced by industrial automation, quality control demands, and environmental monitoring needs.
Positioning
Mesa Laboratories is positioned as a trusted provider of critical validation and monitoring solutions. Its competitive advantages lie in its long-standing expertise in sterilization, its diversified product and service offerings, and its commitment to quality and regulatory compliance. The company serves a niche but essential part of the healthcare and industrial supply chain.
Total Addressable Market (TAM)
The TAM for sterilization indicators, validation services, and process analytics is substantial, encompassing global healthcare, pharmaceuticals, biotechnology, food and beverage, and environmental monitoring sectors. While precise TAM figures are not readily available for Mesa's specific niches, it is estimated to be in the tens of billions of dollars globally. Mesa is a key, though not dominant, player within its specialized segments of this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand reputation and decades of experience in sterilization validation.
- Diversified product and service portfolio serving critical needs.
- Commitment to quality, accuracy, and regulatory compliance.
- Established customer base in healthcare and industrial sectors.
- Experienced management team.
Weaknesses
- Reliance on acquisitions for significant growth in recent years.
- Potential for increased competition from larger players.
- Limited brand recognition outside of its specialized niches.
- Sensitivity to regulatory changes.
Opportunities
- Expansion into emerging markets with growing healthcare infrastructure.
- Development of new digital solutions for data management and analytics.
- Acquisitions of complementary businesses to expand product lines and geographic reach.
- Growing demand for advanced sterilization techniques.
- Increased focus on environmental monitoring and compliance.
Threats
- Economic downturns affecting healthcare and industrial spending.
- Increased competition and pricing pressures.
- Changes in regulatory landscape and compliance requirements.
- Technological disruptions impacting existing product lines.
- Supply chain disruptions and raw material cost volatility.
Competitors and Market Share
Key Competitors
- 3M Company (MMM)
- STERIS plc (STE)
- Cardinal Health, Inc. (CAH)
Competitive Landscape
Mesa Laboratories competes with larger, more diversified companies like 3M and STERIS in the sterilization and validation space, as well as with numerous smaller, specialized providers. Its competitive advantages include its focus on niche markets, specialized expertise, and agility. However, larger competitors may have greater resources for R&D and marketing. In process analytics, competition is fragmented with many players offering specialized solutions.
Major Acquisitions
Sterigenics International LLC
- Year: 2022
- Acquisition Price (USD millions): 3500
- Strategic Rationale: The acquisition of Sterigenics aimed to significantly expand Mesa's sterilization services capabilities, geographic reach, and market position, creating a more comprehensive offering for customers in the pharmaceutical and medical device industries.
Growth Trajectory and Initiatives
Historical Growth: Mesa Laboratories has exhibited a consistent historical growth trajectory, with a significant portion of its expansion fueled by strategic acquisitions. Organic growth has also contributed, driven by new product development and market penetration within its core segments.
Future Projections: Analyst projections for Mesa Laboratories typically anticipate continued revenue growth, supported by ongoing integration of acquired businesses and potential for further strategic M&A. Profitability is expected to improve with operational efficiencies. Growth drivers include the expanding healthcare sector and the increasing need for reliable process analytics.
Recent Initiatives: Recent initiatives have heavily focused on executing its acquisition strategy, integrating newly acquired businesses, and expanding its service offerings. This includes targeted acquisitions aimed at strengthening its market position in sterilization and validation or broadening its process analytics capabilities.
Summary
Mesa Laboratories is a well-established life sciences company with strong expertise in sterilization validation and process analytics. Its growth has been significantly propelled by strategic acquisitions, enhancing its market position and product breadth. While facing competition from larger entities, Mesa leverages its niche focus and quality reputation. Continued success will depend on effective integration of acquisitions and navigating evolving regulatory and market demands.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations (SEC Filings - 10-K, 10-Q)
- Financial news outlets and market data providers
- Industry analysis reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy is based on publicly available information and may not be exhaustive. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesa Laboratories Inc
Exchange NASDAQ | Headquaters Lakewood, CO, United States | ||
IPO Launch date 1995-01-25 | CEO, President & Director Mr. Gary M. Owens | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 730 | Website https://www.mesalabs.com |
Full time employees 730 | Website https://www.mesalabs.com | ||
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.